Get the Stockscreener App
10.75
1.90%
0.2399
Mesoblast Ltd Adr stock is traded at $10.75, with a volume of 10,990.
It is up +1.90% in the last 24 hours and down -15.74% over the past month.
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
See More
Previous Close:
$10.51
Open:
$10.75
24h Volume:
10,990
Relative Volume:
0.05
Market Cap:
$1.61B
Revenue:
$7.50M
Net Income/Loss:
$-81.89M
P/E Ratio:
0.2028
EPS:
53.0176
Net Cash Flow:
$-63.58M
1W Performance:
+0.28%
1M Performance:
-15.74%
6M Performance:
-37.66%
1Y Performance:
+44.15%
1-Day Range:
$10.72
$10.80
1-Week Range:
$10.32
$10.86
52-Week Range:
$5.78
$22.00
Mesoblast Ltd Adr Stock (MESO) Company Profile
Compare MESO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
10.80 | 1.61B | 7.50M | -81.89M | -63.58M | 53.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.18 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
553.57 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.08 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
550.68 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.74 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-24 | Upgrade | Maxim Group | Hold → Buy |
| Aug-29-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-23-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-31-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Downgrade | Maxim Group | Buy → Hold |
| Aug-04-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-04-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-23 | Initiated | William Blair | Outperform |
| Dec-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-06-22 | Initiated | Piper Sandler | Overweight |
| Apr-07-21 | Upgrade | Maxim Group | Hold → Buy |
| Dec-22-20 | Downgrade | Maxim Group | Buy → Hold |
| Dec-04-20 | Downgrade | Chardan Capital Markets | Neutral → Sell |
| Oct-22-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-28-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-31-19 | Resumed | H.C. Wainwright | Buy |
| Mar-22-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Feb-28-18 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-31-17 | Initiated | Oppenheimer | Outperform |
| Jun-08-17 | Initiated | Cantor Fitzgerald | Buy |
View All
Mesoblast Ltd Adr Stock (MESO) Latest News
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD - GlobeNewswire Inc.
All Markets & Instruments Available to Trade - Capital.com
Mesoblast (ASX:MSB) Secures Medicaid Agreement for Ryoncil® - thecapitalclub.com.au
UPDATED: Your guide to February Reporting Season 2020 - Morningstar.com.au
21 Best-Performing Small-Cap Stocks for March 2025 - NerdWallet
Why Mesoblast Ltd ADR (NASDAQ: MESO) Is Worth Including On Your Watchlist - Marketing Sentinel
The 98.76% Simple Moving Average of Mesoblast Ltd ADR’s (MESO) Stock in the Past 200 Days - The News Heater
Mesoblast Ltd ADR (NASDAQ:MESO) Shares Are Up 10.24 Percent In A Week – But Can The Gains Continue? - Marketing Sentinel
ASX Lunch Wrap: ASX and gold reset record highs; but Origin cuts its LNG forecast - Stockhead
Why are Mesoblast shares in a trading halt? - The Motley Fool Australia
Mesoblast Limited Initiates Trading Halt Pending Financing Announcement - TipRanks
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
MESO Stock Surges 80% In A Month After FDA Approval Of GVHD Drug - Barchart
Mesoblast (NASDAQ:MESO) Shares Gap UpWhat's Next? - MarketBeat
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
If You Don’t Buy Safe Pro Group Inc (NASDAQ: SPAI) Now, You’ll Regret It Later - Stocks Register
No Stopping Editas Medicine Inc (NASDAQ: EDIT)’s Stock Plunged? - Stocks Register
Mesoblast Stock Soars to 52-Week High, Hits $19.15 - Investing.com
What Awaits These 4 Biotech Stocks That More Than Doubled In 2024 - Barchart
Mesoblast shares downgraded to hold by Jefferies By Investing.com - Investing.com South Africa
Why the Mesoblast share price is diving 18% after an FDA win - The Motley Fool Australia
Mesoblast share price rockets 30% on big US FDA news - The Motley Fool Australia
Mesoblast stock soars to 52-week high, hits $12.21 - Investing.com
Mesoblast Stock Soars to 52-Week High, Hits $12.19 - Investing.com
Mesoblast stock soars to 52-week high, hits $11.1 - Investing.com
JPMorgan Takes Substantial Stake in Mesoblast Ltd - TipRanks
Mesoblast to raise $50m from top shareholder for product launch - Capital Brief
Mesoblast: Rolling The Dice On Cellular Medicines (NASDAQ:MESO) - Seeking Alpha
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
11 Best ASX Stocks To Buy Now - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Australia stocks higher at close of trade; S&P/ASX 200 up 0.43% - Investing.com
Philip R. Krause, M.D., Former FDA Deputy Chief For Vaccines, Joins Mesoblast Board - Barchart
ASX dives as Trump tests COVID positive - The Australian
The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal - Yahoo Finance
Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology - streetwisereports.com
6 ASX BioTechs Trading on the NASDAQ - TheBull.com.au
Mesoblast Ltd Adr Stock (MESO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.28%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):